Sernova, Seraxis plan merger to form BetaNova Biotherapeutics

Bitget2026/09/25 11:00

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Sernova Biotherapeutics agreed to combine with Seraxis to form BetaNova Biotherapeutics, a U.S.-domiciled clinical-stage company focused on type 1 diabetes.
The merged group is expected to pair Seraxis stem cell-derived pancreatic islet programs with Sernova’s implantable, retrievable Cell Pouch delivery platform.
The combination is slated to close in November 2026, subject to customary closing conditions and approvals.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sernova Biotherapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609250700PRIMZONEFULLFEED9833803) on September 25, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Sernova, Seraxis plan merger to form BetaNova Biotherapeutics

You may also like

Crypto prices